DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mozobil (Plerixafor Subcutaneous) - Published Studies

 
 



Mozobil Related Published Studies

Well-designed clinical trials related to Mozobil (Plerixafor Subcutaneous)

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. [2009.12]

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. [2009.10.01]

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. [2009.06.04]

Other research related to Mozobil (Plerixafor Subcutaneous)

Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. [2011.08.20]

Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. [2011.07]

Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. [2011.06]

Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. [2011.06]

Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program. [2011.05]

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. [2011.05]

Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. [2011.05]

Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. [2011.05]

A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. [2011.04]

Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. [2011.04]

Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. [2011.04]

Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. [2011.04]

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. [2011.03]

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. [2011.03]

The feasibility of plerixafor as a second-line stem cell mobilizing agent in children. [2011.01]

Booster of plerixafor can be successfully used in addition to chemotherapy-based regimen to rescue stem cell mobilization failure. [2010.12.22]

Plerixafor dosing and administration in a patient with dialysis-dependent renal failure. [2010.12]

Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. [2010.12]

Profound blockage of CXCR4 signaling at multiple points using the synergy between plerixafor, mirtazapine, and clotrimazole as a new glioblastoma treatment adjunct. [2010.10]

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. [2010.05.17]

Plerixafor: a peripheral blood stem cell mobilizer. [2010.05]

Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. [2010.05]

Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. [2010.05]

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. [2010.02]

A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. [2010.01]

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. [2010.01]

FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. [2010]

Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer. [2010]

Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs. [2010]

[Stem cell harvesting after plerixafor treatment] [2009.11.16]

[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication] [2009.11.02]

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. [2009.10]

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). [2009.10]

Plerixafor hydrochloride: A novel agent for the mobilization of peripheral blood stem cells. [2009.07]

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). [2009.06.01]

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. [2009.06]

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. [2009.02]

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. [2009.01]

Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma. [2009]

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. [2009]

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. [2008.11]

Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. [2008.11]

Other possibly related research studies

Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. [2008.07.22]

Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. [2010.06.30]

Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. [2010.07]

Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference. [2010.04]

Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. [2010.07.01]

Successful mobilization with AMD3100 and filgrastim with engraftment of autologous peripheral blood stem cells in a heavily pretreated pediatric patient with recurrent Burkitt lymphoma. [2010.03]

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. [2010.03.01]

Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas. [2010.03.01]

Chemokines and chemokine receptors: new insights into cancer-related inflammation. [2010.03]

Successful mobilization, harvest and transplant of peripheral blood stem cells using AMD3100 and G-CSF following high dose craniospinal irradiation for medulloblastoma in a young child. [2010.04]

Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease. [2009]

Intrahypothalamic injection of the HIV-1 envelope glycoprotein induces fever via interaction with the chemokine system. [2010.02]

New agents for mobilizing peripheral blood stem cells. [2009.08]

CXCR4 but not CXCR7 is mainly implicated in ocular leukocyte trafficking during ovalbumin-induced acute uveitis. [2009.10]

New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses. [2009.05.22]

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. [2009.06]

Recent patents regarding the discovery of small molecule CXCR4 antagonists. [2009.01]

Inhibition of the SDF-1/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension. [2009.06.05]

Role of the CXCL12/CXCR4 axis in milky spots of rats bearing ascitic-type hepatoma. [2009.09]

The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. [2009.08]

Modulation of cocaine-induced activity by intracerebral administration of CXCL12. [2009.06.16]

Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. [2009.03]

Differential mobilization of subsets of progenitor cells from the bone marrow. [2009.01.09]

Elevated CXCL12 expression in the bone marrow of NOD mice is associated with altered T cell and stem cell trafficking and diabetes development. [2008.09.15]

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. [2008.09]

The use of growth factors in hematopoietic stem cell transplantation. [2008]

Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition. [2008.07]

The discovery of antiviral agents: ten different compounds, ten different stories. [2008.11]

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. [2008.08.15]

[Establishment of a CXCR4-expressing gastric cancer cell line in nude mice and the effect of AMD 3100 on tumor regression] [2007.11]

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. [2008.02]

Mobilization of peripheral blood stem cells. [2007.10]

Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates. [2007]

Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients. [2007.08]

AMD3100 mobilizes endothelial progenitor cells in mice, but inhibits its biological functions by blocking an autocrine/paracrine regulatory loop of stromal cell derived factor-1 in vitro. [2007.07]

HIV entry inhibitors. [2007.07.07]

Antagonism of stromal cell-derived factor-1alpha reduces infarct size and improves ventricular function after myocardial infarction. [2007.11]

Current developments in the synthesis and biological activity of HIV-1 double-drug inhibitors. [2007]

Low molecular weight fucoidan prevents neointimal hyperplasia after aortic allografting. [2007.05.15]

Dual effect of AMD3100, a CXCR4 antagonist, on bleomycin-induced lung inflammation. [2007.05.01]

Modification of post-myocardial infarction granulocyte-colony stimulating factor therapy with myelo-suppressives. [2007.04]

Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. [2007.04]

Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? [2007.05]

AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. [2007.01]

AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. [2007.02]

Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. [2007.04.15]

Stem cells in acute liver failure. [2011]

[New molecular targets and new clinical practices for hematopoietic stem cell mobilization]. [2011.08.01]

Sonic hedgehog-induced functional recovery after myocardial infarction is enhanced by AMD3100-mediated progenitor-cell mobilization. [2011.06.14]

The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. [2011.07]

Combined effects of hematopoietic progenitor cell mobilization from bone marrow by granulocyte colony stimulating factor and AMD3100 and chemotaxis into the brain using stromal cell-derived factor-1alpha in an Alzheimer's disease mouse model. [2011.07]

Acrolein inhalation prevents vascular endothelial growth factor-induced mobilization of Flk-1+/Sca-1+ cells in mice. [2011.07]

[Expression of SDF-1 in lung tissues and intervention of AMD3100 in asthmatic rats]. [2011.04]

Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. [2011.04]

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. [2011.08]

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? [2011.04.15]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017